ClinicalTrials.gg
CompletedNCT01462370Updated Feb 9, 2022Results posted

Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)

A Phase 3 interventional study of Etoricoxib and Ibuprofen in Dysmenorrhea, sponsored by Organon and Co. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a study to determine the overall analgesic effect of a single oral dose of etoricoxib compared to ibuprofen in participants with moderate-to-severe primary dysmenorrhea.

Read the detailed description

Participants who meet all the study entry criteria will be randomly allocated to 2 possible sequences of the 2 treatment regimens over the course of 2 menstrual cycles.

In treatment sequence 1, participants will receive etoricoxib 120 mg daily in menstrual cycle 1, and ibuprofen up to 2400 mg/daily in menstrual cycle 2. In treatment sequence 2, participants will receive ibuprofen up to 2400 mg/daily in menstrual cycle 1 and etoricoxib 120 mg daily in menstrual cycle 2.

02

Conditions studied

  • Dysmenorrhea

Browse trials for

03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

This study's enrollment of 139 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agree to remain abstinent or use double-barrier throughout the study. Participants who are status post tubal ligation are exempt from this requirement.
  • Moderate or severe primary dysmenorrhea during a minimum of 4 of the previous 6 menstrual cycles. Moderate: Over-the-counter analgesics provide significant relief in most menstrual cycles; discomfort interferes with usual activity. Severe: Over-the-counter analgesics not consistently effective, or prescription analgesics required in at least some menstrual cycles; discomfort is incapacitating causing an inability to work or do usual activity.
  • Willing to limit alcohol intake to 2 drinks or equivalent per day for the duration of the study and follow-up period as well as to avoid exercise during the first 24 hours postdose in each menstrual cycle.
  • Able to read, understand, and complete diary.

Exclusion criteria

Exclusion Criteria:

  • Use of an intrauterine device. Pregnant, breast feeding, or \<6 weeks postpartum.
  • Active gastric ulcer or history of inflammatory bowel disease.
  • Uncontrolled hypertension.
  • Uncontrolled diabetes mellitus or renal disease.
  • Class II-IV congestive heart failure.
  • Coronary artery bypass graft surgery, angioplasty, myocardial infarction, cerebrovascular accident or within the past 6 months.
  • Unstable angina.
  • Mild, moderate, or severe hepatic insufficiency.
  • Any personal or family history of an inherited or acquired bleeding disorder.
  • History of neoplastic disease; Exceptions: 1)adequately treated basal cell carcinoma or carcinoma in situ of the cervix; 2) other which have been successfully treated > or equal to 5 years prior to screening. Participants with a history of leukemia, lymphoma, malignant melanoma, and myeloproliferative disease are ineligible for the study regardless of the time since treatment.
  • Allergic to etoricoxib, ibuprofen, acetaminophen, indomethacin, or other nonsteroidal anti-inflammatory drugs (NSAIDs), or cyclooxygenase (COX)-2 inhibitors, or to components in Saridon (propyphenazone/paracetamol/caffeine).
  • Recent history of chronic analgesic or tranquilizer use or dependence.
  • Morbidly obese and demonstrates significant health problems stemming from the obesity.
  • Current user of recreational or illicit drugs or had a recent history of drug or alcohol abuse or dependence.
  • Participated in another clinical study within the last 4 weeks.
  • Not able to swallow oral medications: surgical or anatomical conditions that will preclude from swallowing and absorbing oral medications on an ongoing basis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen

    Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.

    Drug: Etoricoxib · Drug: Ibuprofen · Drug: Placebo to etoricoxib · Drug: Placebo to ibuprofen · Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg

  • Experimental
    Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen

    Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.

    Drug: Etoricoxib · Drug: Ibuprofen · Drug: Placebo to etoricoxib · Drug: Placebo to ibuprofen · Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg

Interventions

  • Etoricoxib 120 mg tablet given orally for one dose.

  • Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.

  • DrugPlacebo to etoricoxib

    Placebo to etoricoxib, one tablet.

  • DrugPlacebo to ibuprofen

    Placebo to ibuprofen, up to four 3-capsule doses.

  • DrugAcetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg

    Drug page: Acetaminophen

    Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.

    Also known as: Saridon

06

What researchers measure

Primary outcomes

  1. Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose

    TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24, with increasing scores indicating greater pain relief.

    Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours

Secondary outcomes

  1. Sum of Pain Intensity Difference Scores Over the 6-Hour Time Period (SPID6)

    The Pain Intensity Difference (PID) score is the difference between the baseline pain intensity (PI) score and the PI score recorded at each time point post initial dose, as calculated by subtracting the pain intensity at each of the subsequent time points from the baseline pain intensity score; therefore, it is on a -1 to 3 scale, with a large value representing a greater treatment effect. SPID6 is derived by multiplying the PID score at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours and it is on a scale of -6 to 18.

    Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours

  2. Mean Participant Global Evaluation of Pain at 6 Hours After the Initial Dose (GLOBAL6)

    The GLOBAL6 was recorded by the participant at 6 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL6 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.

    Time frame: 6 hours

  3. Mean Participant Global Evaluation of Pain at 24 Hours After the Initial Dose (GLOBAL24)

    The GLOBAL24 was recorded by the participant at 24 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL24 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.

    Time frame: 24 hours

  4. Mean Time to >=1 Unit Improvement From Baseline in Pain Intensity During the 6 Hours After the Initial Dose

    The time to a change from baseline in pain intensity score of \>=1 unit on the pain intensity scale was calculated. The pain intensity scale rates participant pain on a scale of -1 to 3, with larger values associated with greater treatment effect.

    Time frame: Baseline and 6 hours

  5. Peak Pain Intensity Difference (PID) During the 6 Hours After the Initial Dose

    Peak PID during the 6 hours post initial dose is defined as the maximum PID score recorded during first 6 hours after the initial dose of study medication. PID is evaluated on a scale of -1 to 3, with larger values representing a greater treatment effect.

    Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours

  6. Peak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose

    Peak PR during the 6 hours post initial dose is defined as the maximum PR score recorded during the first 6 hours after the initial dose of study medication. PR is recorded on a scale of 0 to 4, with 0 = no pain relief, 1 = little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.

    Time frame: Up to 6 hours

  7. Number of Participants Using Rescue Medication 24 Hours After the Initial Dose

    Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg (Saridon) was provided to each participant as rescue medication. Participants were permitted to take 2 tablets at a time and up to 3 doses within 24 hours of dosing of study drug for rescue purposes.

    Time frame: 24 Hours

  8. PID at Up to 12 Hours Following the Initial Dose

    PID during the 12 hours following the initial dose is defined as the maximum PID score recorded during first 12 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.

    Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 and 12 hours

  9. PR at Up to 12 Hours Following the Initial Dose

    PR during the 12 hours following the initial dose is defined as the maximum PR score recorded during the first 12 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.

    Time frame: Up to 12 hours

  10. PID at Up to 24 Hours Following the Initial Dose

    PID during the 24 hours following the initial dose is defined as the maximum PID score recorded during first 24 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.

    Time frame: Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 20 and 24 hours

  11. PR at Up to 24 Hours Following the Initial Dose

    PR during the 24 hours following the initial dose is defined as the maximum PR score recorded during the first 24 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.

    Time frame: Up to 24 hours

  12. Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 6 Hours After the Initial Dose

    At 6 hours following the initial dose. participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 6 hours post initial dose were summed.

    Time frame: 6 hours

  13. Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose

    At 24 hours following the initial dose of study medication, participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 24 hours post initial dose were summed.

    Time frame: 24 Hours

07

Results

Posted Jul 10, 2013

Participant flow

Participant flow — Overall Study
MilestoneEtoricoxib 120 mg/ Ibuprofen Up to 2400 mgIbuprofen Up to 2400 mg / Etoricoxib 120 mg
Started6970
Completed6865
Not completed15
Withdrew: Lack of qualifying event11
Withdrew: Physician decision01
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryTotal Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose

TOPAR6 was calculated by multiplying the pain relief (PR) score (0- to 4-point scale, with 0=None, and 4=Complete for pain relief) at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours post the initial Day 1 dose. The range of TOPAR6 score is 0 to 24, with increasing scores indicating greater pain relief.

Time frame:
Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours
Reported as:
Least squares mean · Score on a Scale
Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose17.38 ± 0.3716.49 ± 0.37
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.043 (A priori threshold for statistical significance = \<0.025 (one-sided).) · Difference in ls means: 0.89 · 95% CI 0.03 to 1.76Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondarySum of Pain Intensity Difference Scores Over the 6-Hour Time Period (SPID6)

The Pain Intensity Difference (PID) score is the difference between the baseline pain intensity (PI) score and the PI score recorded at each time point post initial dose, as calculated by subtracting the pain intensity at each of the subsequent time points from the baseline pain intensity score; therefore, it is on a -1 to 3 scale, with a large value representing a greater treatment effect. SPID6 is derived by multiplying the PID score at each time point by the duration (in hours) since the preceding time point, and summing these weighted values up to 6 hours and it is on a scale of -6 to 18.

Time frame:
Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours
Reported as:
Least squares mean · Score on a Scale
Sum of Pain Intensity Difference Scores Over the 6-Hour Time Period (SPID6)
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
Sum of Pain Intensity Difference Scores Over the 6-Hour Time Period (SPID6)9.48 ± 0.589.27 ± 0.58
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.768 (A nominal threshold for statistical significance = \<0.05.) · Difference in ls means: 0.20 · 95% CI -1.16 to 1.57Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryMean Participant Global Evaluation of Pain at 6 Hours After the Initial Dose (GLOBAL6)

The GLOBAL6 was recorded by the participant at 6 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL6 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.

Time frame:
6 hours
Reported as:
Least squares mean · Score on a Scale
Mean Participant Global Evaluation of Pain at 6 Hours After the Initial Dose (GLOBAL6)
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
Mean Participant Global Evaluation of Pain at 6 Hours After the Initial Dose (GLOBAL6)2.50 ± 0.082.24 ± 0.08
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.007 (A nominal threshold for statistical significance = \<0.05.) · Difference in ls means: 0.26 · 95% CI 0.07 to 0.45Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryMean Participant Global Evaluation of Pain at 24 Hours After the Initial Dose (GLOBAL24)

The GLOBAL24 was recorded by the participant at 24 hours (or at the time of rescue medication use) after taking the first dose of study medication. The GLOBAL24 uses a pain relief scale of 0 to 4, where 0 = poor pain relief, 1 = fair pain relief, 2 = good pain relief, 3 = very good pain relief, and 4 = excellent pain relief.

Time frame:
24 hours
Reported as:
Least squares mean · Score on a Scale
Mean Participant Global Evaluation of Pain at 24 Hours After the Initial Dose (GLOBAL24)
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
Mean Participant Global Evaluation of Pain at 24 Hours After the Initial Dose (GLOBAL24)2.65 ± 0.082.29 ± 0.08
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = <0.001 (A nominal threshold for statistical significance = \<0.05.) · Difference in ls means: 0.36 · 95% CI 0.17 to 0.54Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryMean Time to >=1 Unit Improvement From Baseline in Pain Intensity During the 6 Hours After the Initial Dose

The time to a change from baseline in pain intensity score of \>=1 unit on the pain intensity scale was calculated. The pain intensity scale rates participant pain on a scale of -1 to 3, with larger values associated with greater treatment effect.

Time frame:
Baseline and 6 hours
Reported as:
Mean · Hours
Mean Time to >=1 Unit Improvement From Baseline in Pain Intensity During the 6 Hours After the Initial Dose
HoursEtoricoxib 120 mgIbuprofen up to 2400 mg
Mean Time to >=1 Unit Improvement From Baseline in Pain Intensity During the 6 Hours After the Initial Dose1.0 (1.0 to 1.5)1.5 (1.0 to 1.5)
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · Regression, Cox · p = 0.371 (A priori threshold for statistical significance = \<0.05.) · Odds ratio (or): 0.89 · 95% CI 0.70 to 1.14Adjusted for treatment, period, and baseline pain intensity.
SecondaryPeak Pain Intensity Difference (PID) During the 6 Hours After the Initial Dose

Peak PID during the 6 hours post initial dose is defined as the maximum PID score recorded during first 6 hours after the initial dose of study medication. PID is evaluated on a scale of -1 to 3, with larger values representing a greater treatment effect.

Time frame:
Baseline and 0.5, 1, 1.5, 2, 3, 4, 5 and 6 hours
Reported as:
Least squares mean · Score on a Scale
Peak Pain Intensity Difference (PID) During the 6 Hours After the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
Peak Pain Intensity Difference (PID) During the 6 Hours After the Initial Dose2.2 ± 0.42.1 ± 0.4
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.051 (A priori threshold for statistical significance = \<0.05.) · Difference in ls means: 0.10 · 95% CI -0.00 to 0.20Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryPeak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose

Peak PR during the 6 hours post initial dose is defined as the maximum PR score recorded during the first 6 hours after the initial dose of study medication. PR is recorded on a scale of 0 to 4, with 0 = no pain relief, 1 = little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.

Time frame:
Up to 6 hours
Reported as:
Least squares mean · Score on a Scale
Peak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
Peak Pain Relief (Peak PR) During the 6 Hours After the Initial Dose3.70 ± 0.063.52 ± 0.06
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.019 (A priori threshold for statistical significance = \<0.05.) · Mean difference in ls means: 0.17 · 95% CI 0.03 to 0.32Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryNumber of Participants Using Rescue Medication 24 Hours After the Initial Dose

Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg (Saridon) was provided to each participant as rescue medication. Participants were permitted to take 2 tablets at a time and up to 3 doses within 24 hours of dosing of study drug for rescue purposes.

Time frame:
24 Hours
Reported as:
Number · Participants
Number of Participants Using Rescue Medication 24 Hours After the Initial Dose
ParticipantsEtoricoxib 120 mgIbuprofen up to 2400 mg
Number of Participants Using Rescue Medication 24 Hours After the Initial Dose14
SecondaryPID at Up to 12 Hours Following the Initial Dose

PID during the 12 hours following the initial dose is defined as the maximum PID score recorded during first 12 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.

Time frame:
Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 and 12 hours
Reported as:
Least squares mean · Score on a Scale
PID at Up to 12 Hours Following the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
PID at Up to 12 Hours Following the Initial Dose2.28 ± 0.042.07 ± 0.04
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = <0.001 (A priori threshold for statistical significance = \<0.05.) · Difference in ls means: 0.21 · 95% CI 0.10 to 0.31Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryPR at Up to 12 Hours Following the Initial Dose

PR during the 12 hours following the initial dose is defined as the maximum PR score recorded during the first 12 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.

Time frame:
Up to 12 hours
Reported as:
Least squares mean · Score on a Scale
PR at Up to 12 Hours Following the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
PR at Up to 12 Hours Following the Initial Dose3.73 ± 0.073.45 ± 0.07
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.002 (A priori threshold for statistical significance = \<0.05.) · Difference in ls means: 0.28 · 95% CI 0.10 to 0.45Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryPID at Up to 24 Hours Following the Initial Dose

PID during the 24 hours following the initial dose is defined as the maximum PID score recorded during first 24 hours after the initial dose of study medication. PID is evaluated on a scale from 0 to 3, with 0 = no pain, 1 = slight pain, 2 = moderate pain, and 3 = severe pain.

Time frame:
Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 20 and 24 hours
Reported as:
Least squares mean · Score on a Scale
PID at Up to 24 Hours Following the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
PID at Up to 24 Hours Following the Initial Dose2.36 ± 0.042.25 ± 0.04
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.011 (A priori threshold for statistical significance = \<0.05.) · Difference in ls means: 0.11 · 95% CI 0.03 to 0.20Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryPR at Up to 24 Hours Following the Initial Dose

PR during the 24 hours following the initial dose is defined as the maximum PR score recorded during the first 24 hours after the initial dose of study medication. PR is evaluated on a scale of 0 to 4, with 0 = no pain relief, 1= a little pain relief, 2 = some pain relief, 3 = a lot of pain relief, and 4 = complete pain relief.

Time frame:
Up to 24 hours
Reported as:
Least squares mean · Score on a Scale
PR at Up to 24 Hours Following the Initial Dose
Score on a ScaleEtoricoxib 120 mgIbuprofen up to 2400 mg
PR at Up to 24 Hours Following the Initial Dose3.88 ± 0.073.62 ± 0.07
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · ANOVA · p = 0.004 (A priori threshold for statistical significance = \<0.05.) · Difference in ls means: 0.26 · 95% CI 0.08 to 0.44Adjusted for treatment, period, sequence, patient (sequence), and baseline pain intensity (moderate or severe).
SecondaryNumber of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 6 Hours After the Initial Dose

At 6 hours following the initial dose. participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 6 hours post initial dose were summed.

Time frame:
6 hours
Reported as:
Number · Participants
Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 6 Hours After the Initial Dose
ParticipantsEtoricoxib 120 mgIbuprofen up to 2400 mg
Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 6 Hours After the Initial Dose111103
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · Regression, Logistic · p = 0.112 (A priori threshold for statistical significance = \<0.05.) · Odds ratio (or): 1.60 · 95% CI 0.90 to 2.87Adjusted for treatment, period, and baseline pain intensity.
SecondaryNumber of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose

At 24 hours following the initial dose of study medication, participants were asked to rate their perception of pain control as poor, fair, good, very good, or excellent. The number of participants that reported good, very good, or excellent pain control at 24 hours post initial dose were summed.

Time frame:
24 Hours
Reported as:
Number · Participants
Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose
ParticipantsEtoricoxib 120 mgIbuprofen up to 2400 mg
Number of Participants With a Global Evaluation of Study Medication of Good, Very Good, or Excellent at 24 Hours After the Initial Dose113101
Statistical analysis
  • Etoricoxib 120 mg vs Ibuprofen up to 2400 mg · Regression, Logistic · p = 0.019 (A priori threshold for statistical significance = \<0.05.) · Odds ratio (or): 1.97 · 95% CI 1.12 to 3.45Adjusted for treatment, period, and baseline pain intensity.

Adverse events

Collected over From the time of the initial (first) dose of study medication up to 14 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etoricoxib 120 mg / Ibuprofen up to 2400 mg/Daily—0/69 (0%)0/69 (0%)
Ibuprofen up to 2400 mg / Etoricoxib 120 mg—0/70 (0%)0/70 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)All Randomized Participants
<=20 years14
21-29 years118
>=30 years7
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female139
Male0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Yu Q, Zhu X, Zhang X, Zhang Y, Li X, Hua Q, Chang Q, Zou Q, Di W, Yao Y, Yu W, Liu J, Mehta A, Yan L. Etoricoxib in the treatment of primary dysmenorrhea in Chinese patients: a randomized controlled trial. Curr Med Res Opin. 2014 Sep;30(9):1863-70. doi: 10.1185/03007995.2014.925437. Epub 2014 Jun 30. PubMed 24960147 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Oct 31, 2011
Start
Nov 2011
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Jul 10, 2013
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01462370
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 31, 2011
Start date
Nov 2011
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Jul 10, 2013
Last update
Feb 9, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etoricoxib · Ibuprofen

Start the discussion